التداخل بين برافاستاتين وسوفوسبوفير وفيلباتاسفير

Pravastatin sodium plasma levels can be significantly increased with concomitant administration of inhibitors of OATP1B1.

Pravastatin may be administered with VOSEVI at a dose that does not exceed pravastatin 40 mg. rosuvastatin ↑ rosuvastatin Coadministration of VOSEVI with rosuvastatin may significantly increase the concentration of rosuvastatin which is associated with increased risk of myopathy, including rhabdomyolysis.

HMG-CoA Reductase Inhibitors: pravastatin ↑ pravastatin Coadministration of VOSEVI with pravastatin has been shown to increase the concentration of pravastatin, which is associated with increased risk of myopathy, including rhabdomyolysis.

Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis.

Use the lowest approved statin dose.

If higher doses are needed, use the lowest necessary statin dose based on a risk/benefit assessment.